VIVUS Adds Two New Members to the Board of Directors
October 29 2018 - 7:30AM
Karen Ferrell and Edward A. Kangas Expand
VIVUS’ Board to Nine Members
VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a
biopharmaceutical company, today announced that Karen Ferrell and
Edward A. Kangas have been appointed to VIVUS’ board of directors.
With these appointments, VIVUS’ board of directors expands to nine
members in total.
“We welcome Karen and Ed, both of whom bring
significant board experience including corporate governance,
healthcare, managed care, finance and pharmaceuticals,” said John
Amos, Chief Executive Officer at VIVUS. “Each is a well-respected
leader and together they bring excellent and differentiated skill
sets that will be vital in guiding VIVUS forward. We look forward
to their valuable insights and contributions as we continue our
focus on building a sustainable and profitable company.”
Ms. Ferrell is currently the Executive Chairman
and Chief Executive Officer at Glenridge HealthCare Solutions, a
national tech-enabled network solutions company focused on helping
clients build and maintain efficient, cost-effective, high quality
networks for commercial, managed Medicaid, Medicare Advantage and
other governmental programs. Ms. Ferrell previously held Chief
Executive Officer positions at Zest Health and Apollo Health
Street. Prior to those roles, she served as Senior Vice President
of Provider Contracting and Medical Management for CIGNA
Healthcare, where she was responsible for managing $32 billion in
medical costs for more than 12 million members. Ms. Ferrell’s other
leadership positions include President of Aetna Healthplans of
Florida, Executive Director at Scripps Health and Vice President of
Provider Contracting at Prudential HealthCare. Additionally, she
serves on a number of boards including Alacura, Advantum and
Glenridge HealthCare Solutions. Ms. Ferrell received an M.B.A. from
Pepperdine University.
Mr. Kangas served as Global Chairman and Chief
Executive Officer of Deloitte, an international public accounting
and consulting firm, until his retirement in 2000. He previously
served as the Managing Partner of Deloitte & Touche (USA) and
Managing Partner and Chief Executive Officer of Touche Ross. Mr.
Kangas currently serves as a director of two other public
companies, Hovnanian Enterprises, Inc. and Tenet Healthcare
Corporation, as well as a director of Intelsat S.A., a foreign
private issuer with the SEC. He also serves as Chairman of the
Board of Deutsche Bank USA Corp., a privately held subsidiary of
Deutsche Bank AG. He formerly served as a director of EDS,
Allscripts Healthcare Solutions, Inc., Eclipsys Corporation, Intuit
Inc. and United Technologies Corporation. In addition, he is a past
Chairman of the Board of the National Multiple Sclerosis Society.
Mr. Kangas is also a member of Beta Gamma Sigma Directors’ Table
and a life trustee of the board of trustees of the Kansas
University Endowment Association. In 2010, he was named by the
National Association of Corporate Directors (NACD) to its Directors
Hall of Fame. Mr. Kangas received a B.A. in business administration
and an M.B.A. from the University of Kansas. Mr. Kangas is a
Certified Public Accountant.
About VIVUS
VIVUS is a biopharmaceutical company committed
to the development and commercialization of innovative therapies
that focus on advancing treatments for patients with serious unmet
medical needs. For more information about the Company, please visit
www.vivus.com.
Forward-Looking Statements
Certain statements in this press release are
forward-looking within the meaning of the Private Securities
Litigation Reform Act of 1995 and are subject to risks,
uncertainties and other factors, including risks and uncertainties
related to potential change in our business strategy to enhance
long-term stockholder value; and risks and uncertainties related to
the impact, if any, of changes to our Board of Directors and senior
management team. These risks and uncertainties could cause actual
results to differ materially from those referred to in these
forward-looking statements. The reader is cautioned not to rely on
these forward-looking statements. Investors should read the risk
factors set forth in VIVUS’ Form 10-K for the year ended December
31, 2017 as filed on March 14, 2018, and as amended by the Form
10-K/A filed on April 26, 2018, and periodic reports filed with the
Securities and Exchange Commission. VIVUS does not undertake an
obligation to update or revise any forward-looking statements.
VIVUS,
Inc.
Investor Relations: Lazar PartnersMark Oki
David
CareyChief Financial
Officer
Managing Directoroki@vivus.com
dcarey@lazarpartners.com650-934-5200
212-867-1768
VIVUS (NASDAQ:VVUS)
Historical Stock Chart
From Aug 2024 to Sep 2024
VIVUS (NASDAQ:VVUS)
Historical Stock Chart
From Sep 2023 to Sep 2024